Physician profile
Mark C Gibson
NPI 1437133444
$1,598.72
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $66.56 · 2021: $120 · 2022: $239 · 2023: $362 · 2024: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $419.11 | 2022-2024 | Infuse, Ultra Multifocal Toric, Vyzulta |
| Alcon Vision LLC | $228.08 | 2019-2024 | Total30 |
| Johnson & Johnson Vision Care, INC. | $219.54 | 2020-2023 | Acuvue |
| Coopervision INC. | $203.26 | 2022-2024 | Cvi Contact Lens, Clariti Contact Lens |
| Aerie Pharmaceuticals, INC. | $125.00 | 2019 | |
| Genzyme Corporation | $121.35 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $117.06 | 2019 | |
| Dompe US, INC. | $70.38 | 2024 | Oxervate |
| Biotissue Holdings INC. | $42.78 | 2024 | |
| Harrow Eye, LLC | $18.56 | 2024 | Ilevro |
| Abbvie INC. | $17.47 | 2022 | |
| Allergan, INC. | $16.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.